Escalation of Antibiotic Therapy for Hospital-Acquired Pneumonia

Assessment and Escalation of Antibiotic Therapy

For a patient with hospital-acquired pneumonia experiencing persistent breakthrough fevers, the Infectious Diseases Society of America recommends escalation to a combination therapy of a carbapenem plus vancomycin or linezolid, with consideration of adding an aminoglycoside in cases of high mortality risk 1, 2, 3
The American Thoracic Society suggests that persistent fever alone in a stable patient is rarely an indication to alter the antibiotic regimen 4
Clinical deterioration or culture results should guide changes rather than fever pattern alone, as recommended by the Infectious Diseases Society of America 4
Risk factors for mortality include need for ventilatory support and septic shock, according to the Society of Critical Care Medicine 1, 3
Risk factors for multidrug-resistant organisms include prior intravenous antibiotic use within 90 days, as stated by the Centers for Disease Control and Prevention 5

For patients at high risk of mortality, the Infectious Diseases Society of America recommends switching to a two-drug gram-negative regimen plus MRSA coverage, such as meropenem plus vancomycin or linezolid 1, 2, 3
The American College of Chest Physicians suggests considering adding an aminoglycoside, such as amikacin, in cases of suspected MDR Pseudomonas 1, 2, 6
For patients not at high risk of mortality but with prior antibiotic exposure, the Infectious Diseases Society of America recommends switching to a different antipseudomonal agent plus MRSA coverage, such as cefepime plus vancomycin or meropenem 1, 2, 3

The Infectious Diseases Society of America advises against adding vancomycin empirically for persistent fever alone if blood cultures are negative after 48 hours 4
The Society of Critical Care Medicine recommends avoiding redundant β-lactam coverage and delaying escalation in patients with clinical deterioration or septic shock 1, 2
The American Thoracic Society suggests de-escalating antibiotic therapy once culture results are available to prevent emergence of resistance 1, 4

The Centers for Disease Control and Prevention recommends that local resistance patterns should inform the choice of empiric therapy 5
The Infectious Diseases Society of America suggests that prior MRSA colonization increases the risk of MRSA pneumonia and should prompt coverage 1, 3
Units with high MRSA prevalence among S. aureus isolates should include MRSA coverage in the escalation regimen, as recommended by the Society of Healthcare Epidemiology of America 1, 3